Mechanism of immune evasion in breast cancer

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
   PubMed Web of Science ®Google Scholar
• SchreiberRDOldLJSmythMJCancer immunoediting: integrating immunity’s roles in cancer suppression and promotionScience201133160241565157021436444
   PubMed Web of Science ®Google Scholar
• VeselyMDKershawMHSchreiberRDSmythMJNatural innate and adaptive immunity to cancerAnnu Rev Immunol20112923527121219185
   PubMed Web of Science ®Google Scholar
• JiangXShapiroDJThe immune system and inflammation in breast cancerMol Cell Endocrinol201438267368223791814
   PubMedGoogle Scholar
• ChuNJArmstrongTDJaffeeEMNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionClin Cancer Res20152171549155725623216
   PubMed Web of Science ®Google Scholar
• BoyleSTKochetkovaMBreast cancer stem cells and the immune system: promotion, evasion and therapyJ Mammary Gland Biol Neoplasia201419220321124997735
   PubMed Web of Science ®Google Scholar
• TöpferKKempeSMüllerNTumor evasion from T cell surveillanceJ Biomed Biotechnol2011201191847122190859
   PubMedGoogle Scholar
• ErnstMPutoczkiTLStat3: linking inflammation to (gastrointestinal) tumourigenesisClin Exp Pharmacol Physiol201239871171822211709
   PubMedGoogle Scholar
• WhitesideTLImmune responses to malignanciesJ Allergy Clin Immunol20101252 Suppl 2S272S28320061007
   PubMed Web of Science ®Google Scholar
• HouSYSangMXGengCZExpressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanismArch Med Res2014451445124316396
   PubMedGoogle Scholar
• XuXTangXLuMOverexpression of MAGE-A9 predicts unfavorable outcome in breast cancerExp Mol Pathol201497357958425445503
   PubMedGoogle Scholar
• TchouJWangLCSelvenBMesothelin, a novel immunotherapy target for triple negative breast cancerBreast Cancer Res Treat2012133279980422418702
   PubMed Web of Science ®Google Scholar
• BarićMKulićASirotković-SkerlevMCirculating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpressionPathol Oncol Res201521358959525367073
   PubMedGoogle Scholar
• LinnemannCSchumacherTNBendleGMT-cell receptor gene therapy: critical parameters for clinical successJ Invest Dermatol201113191806181621677669
   PubMedGoogle Scholar
• GrayMATaoRNDePorterSMSpiegelDAMcNaughtonBRA nanobody activation immunotherapeutic that selectively destroys HER2-positive breast cancer cellsChembiochem201617215515826556305
   PubMedGoogle Scholar
• FuDGeschwindJFKarthikeyanSMetabolic perturbation sensitizes human breast cancer to NK cell-mediated cytotoxicity by increasing the expression of MHC class I chain-related A/BOncoimmunology20154e99122825949910
   PubMedGoogle Scholar
• SeligerBMaeurerMJFerroneSAntigen-processing machinery breakdown and tumor growthImmunol Today200021945546410953098
   PubMedGoogle Scholar
• LiuYKomoharaYDomenickNExpression of antigen processing and presenting molecules in brain metastasis of breast cancerCancer Immunol Immunother201261678980122065046
   PubMed Web of Science ®Google Scholar
• CampoliMFerroneSTumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligandsTissue Antigens200872432133418700879
   PubMedGoogle Scholar
• KönigLKasimir-BauerSHoffmannOThe prognostic impact of soluble and vesicular HLA-G and its relationship to circulating tumor cells in neoadjuvant treated breast cancer patientsHuman Immunol201677979179926796737
   PubMedGoogle Scholar
• IshibashiKKumaiTOhkuriTEpigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapyOncoimmunology201656e116935627471649
   PubMedGoogle Scholar
• HaghiMHosseinpour FeiziMASadeghizadehMLotfiAS14-bp insertion/deletion polymorphism of the HLA-G gene in breast cancer among women from North Western IranAsian Pac J Cancer Prev201516146155615826320511
   PubMedGoogle Scholar
• JeongSParkSParkBWParkYKwonOJKimHSHuman leukocyte antigen-G (HLA-G) polymorphism and expression in breast cancer patientsPLoS One201495e9828424870375
   PubMed Web of Science ®Google Scholar
• UrosevicMDummerRHuman leukocyte antigen-G and cancer immunoeditingCancer Res200868362763018245459
   PubMedGoogle Scholar
• GuoYChangHLiJThymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathwayApoptosis20152081109112126002438
   PubMed Web of Science ®Google Scholar
• WongRSApoptosis in cancer: from pathogenesis to treatmentJ Exp Clin Cancer Res2011308721943236
   PubMed Web of Science ®Google Scholar
• BębenekMDuśDKoźlakJPrognostic value of the Fas/Fas ligand system in breast cancerContemp Oncol (Pozn)201317212012223788976
   PubMedGoogle Scholar
• Olimón-AndalónVAguilar-LemarroyARatkovich-GonzálezSProapoptotic CD95L levels in normal human serum and sera of breast cancer patientsTumour Biol20153653669367825557789
   PubMedGoogle Scholar
• KimREmiMTanabeKUchidaYTogeTThe role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapyCancer2004100112281229115160330
   PubMedGoogle Scholar
• CoombsMRHarrisonMEHoskinDWApigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cellsCancer Lett2016380242443327378243
   PubMed Web of Science ®Google Scholar
• JadusMRNatividadJMaiALung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionClin Dev Immunol2012201216072422899945
   PubMed Web of Science ®Google Scholar
• WangXSunQLiuQWangCYaoRWangYCTC immune escape mediated by PD-L1Med Hypotheses20169313813927372873
   PubMedGoogle Scholar
• LiZDongPRenMPD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patientJ Cancer20167778479327162536
   PubMed Web of Science ®Google Scholar
• LiCWLimSOXiaWGlycosylation and stabilization of programmed death ligand-1 suppresses T-cell activityNat Commun201671263227572267
   PubMed Web of Science ®Google Scholar
• AlHossinyMLuoLFrazierWRLy6E/K signaling to TGFβ promotes breast cancer progression, immune escape, and drug resistanceCancer Res201676113376338627197181
   PubMedGoogle Scholar
• BertucciFFinettiPColpaertCPDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapyOncotarget2015615135061351925940795
   PubMedGoogle Scholar
• BertucciFFinettiPBirnbaumDMamessierEThe PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancersOncoimmunology201553e108514827141340
   PubMedGoogle Scholar
• McCullarBPandeyMYaghmourGGenomic landscape of small cell carcinoma of the breast contrasted to small cell carcinoma of the lungBreast Cancer Res Treat2016158119520227329168
   PubMedGoogle Scholar
• GröschelSBommerMHutterBIntegration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with PDL1 amplificationCold Spring Harb Mol Case Stud201626a00118027900363
   PubMedGoogle Scholar
• SolimanHKhalilFAntoniaSPD-L1 expression is increased in a subset of basal type breast cancer cellsPLoS One201492e8855724551119
   PubMed Web of Science ®Google Scholar
• BeckersRKSelingerCIVilainRProgrammed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcomeHistopathology2016691253426588661
   PubMed Web of Science ®Google Scholar
• GuoLLiWZhuXPD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarkerSpringerplus20165180527390646
   PubMedGoogle Scholar
• SabatierRFinettiPMamessierEPrognostic and predictive value of PDL1 expression in breast cancerOncotarget2015675449546425669979
   PubMedGoogle Scholar
• MazelMJacotWPantelKFrequent expression of PD-L1 on circulating breast cancer cellsMol Oncol2015991773178226093818
   PubMed Web of Science ®Google Scholar
• ChatterjeeSLesniakWGGabrielsonMA humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumorsOncotarget201679102151022726848870
   PubMedGoogle Scholar
• PusztaiLLadányiASzékelyBDankMImmunotherapy opportunities in breast cancerMagy Onkol20166013440 Hungarian [with English abstract]26934349
   PubMedGoogle Scholar
• García-TeijidoPCabalMLFernándezIPPérezYFTumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targetingClin Med Insights Oncol201610Suppl 1313927081325
   PubMedGoogle Scholar
• LuLXuXZhangBZhangRJiHWangXCombined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugsJ Transl Med2014123624502656
   PubMed Web of Science ®Google Scholar
• LoiSDushyanthenSBeavisPARAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitorsClin Cancer Res20162261499150926515496
   PubMed Web of Science ®Google Scholar
• BlackMBarsoumIBTruesdellPActivation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasisOncotarget201679105571056726859684
   PubMedGoogle Scholar
• KulkarniANatarajanSKChandrasekarVPandeyPRSenguptaSCombining immune checkpoint inhibitors and kinase-inhibiting supramolecular therapeutics for enhanced anticancer efficacyACS Nano Epub2016929
   Google Scholar
• MallCSckiselGDProiaDARepeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerOncoimmunology201552e107511427057446
   PubMedGoogle Scholar
• XuZShenJWangMHComprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancerOncoimmunology201658e120784127622076
   PubMedGoogle Scholar
• HamedEAZakharyMMMaximousDWApoptosis, angiogenesis, inflammation, and oxidative stress: basic interactions in patients with early and metastatic breast cancerJ Cancer Res Clin Oncol20121386999100922362301
   PubMed Web of Science ®Google Scholar
• FuldaSMeyerEDebatinKMInhibition of TRAIL-induced apoptosis by Bcl-2 overexpressionOncogene200221152283229411948412
   PubMed Web of Science ®Google Scholar
• ZhivotovskyBOrreniusSCarcinogenesis and apoptosis: paradigms and paradoxesCarcinogenesis200627101939194516606631
   PubMed Web of Science ®Google Scholar
• JägerRHerzerUSchenkelJWeiherHOverexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic miceOncogene19971515178717959362445
   PubMedGoogle Scholar
• RyanBMKonecnyGEKahlertSSurvivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1Ann Oncol200617459760416403812
   PubMed Web of Science ®Google Scholar
• KhanSFerguson BennitHAsuncion ValenzuelaMMLocalization and upregulation of survivin in cancer health disparities: a clinical perspectiveBiologics20159576726185415
   PubMedGoogle Scholar
• DevarajanESahinAAChenJSDown-regulation of caspase 3 in breast cancer: a possible mechanism for chemoresistanceOncogene200221578843885112483536
   PubMed Web of Science ®Google Scholar
• GrigorievMYPozharisskyKMHansonKPImyanitovENZhivotovskyBExpression of caspase-3 and -7 does not correlate with the extent of apoptosis in primary breast carcinomasCell Cycle20021533734212461296
   PubMedGoogle Scholar
• DuechlerMPeczekLZukKZalesnaIJeziorskiACzyzMThe heterogeneous immune microenvironment in breast cancer is affected by hypoxia-related genesImmunobiology2014219215816524091277
   PubMedGoogle Scholar
• QuigleyDAKristensenVPredicting prognosis and therapeutic response from interactions between lymphocytes and tumor cellsMol Oncol20159102054206226607741
   PubMed Web of Science ®Google Scholar
• NagorsenDScheibenbogenCMarincolaFMLetschAKeilholzUNatural T cell immunity against cancerClin Cancer Res20039124296430314555498
   PubMed Web of Science ®Google Scholar
• PourchetAFuhrmannSRPilonesKACD8(+) T-cell immune evasion enables oncolytic virus immunotherapyEBioMedicine20165596727077112
   PubMedGoogle Scholar
• ColomboMPPiconeseSRegulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapyNat Rev Cancer200771188088717957190
   PubMedGoogle Scholar
• ChaputNLouafiSBardierAIdentification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissueGut200958452052919022917
   PubMed Web of Science ®Google Scholar
• EngelJBHonigAKappMMechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1Arch Gynecol Obstet2014289114114723828443
   PubMed Web of Science ®Google Scholar
• JanikashviliNBonnotteBKatsanisELarmonierNThe dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced toleranceClin Dev Immunol2011201143039422110524
   PubMed Web of Science ®Google Scholar
• LoyherPLRochefortJBaudesson de ChanvilleCCCR2 influences T regulatory cell migration to tumors and serves as a biomarker of cyclophosphamide sensitivityCancer Res Epub2016928
   PubMedGoogle Scholar
• FreierCPKuhnCEndresSFOXP3+ cells recruited by CCL22 into breast cancer correlates with less tumor nodal infiltrationAnticancer Res20163663139314527272839
   PubMedGoogle Scholar
• HossainDMPandaAKChakrabartySMEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieuImmunology2015144456157325284464
   PubMed Web of Science ®Google Scholar
• GelaoLCriscitielloCEspositoADendritic cell-based vaccines: clinical applications in breast cancerImmunotherapy20146334936024762078
   PubMed Web of Science ®Google Scholar
• FrickeIGabrilovichDIDendritic cells and tumor microenvironment: a dangerous liaisonImmunol Invest2006353–445948316916762
   PubMed Web of Science ®Google Scholar
• BellDChomaratPBroylesDIn breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areasJ Exp Med1999190101417142610562317
   PubMed Web of Science ®Google Scholar
• BaiXFLiuJLiOZhengPLiuYAntigenic drift as a mechanism for tumor evasion of destruction by cytolytic T lymphocytesJ Clin Invest2003111101487149612750398
   PubMed Web of Science ®Google Scholar
• da CunhaAMichelinMAMurtaEFPattern response of dendritic cells in the tumor microenvironment and breast cancerWorld J Clin Oncol20145349550225114862
   PubMedGoogle Scholar
• FarrenMRCarlsonLMNetherbyCSTumor-induced STAT3 signaling in myeloid cells impairs dendritic cell generation by decreasing PKCβII abundanceSci Signal20147313ra1624550541
   PubMedGoogle Scholar
• Baragaño RanerosAMartín-PalancoVFernandezAFMethylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemiaGenes Immun2015161718225393931
   PubMed Web of Science ®Google Scholar
• CoudertJDZimmerJTomaselloEAltered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cellsBlood200510651711171715886320
   PubMed Web of Science ®Google Scholar
• LeeJCLeeKMKimDWHeoDSElevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patientsJ Immunol2004172127335734015187109
   PubMedGoogle Scholar
• CraneCAAustgenKHaberthurKImmune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patientsProc Natl Acad Sci U S A201411135128231282825136121
   PubMed Web of Science ®Google Scholar
• El-GazzarACaiXReevesRSEffects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cellsOncogene201433414932494024141776
   PubMedGoogle Scholar
• Esquivel-VelázquezMOstoa-SalomaPPalacios-ArreolaMINava-CastroKECastroJIMorales-MontorJThe role of cytokines in breast cancer development and progressionJ Interferon Cytokine Res201535111625068787
   PubMed Web of Science ®Google Scholar
• GunaydinGKesikliSAGucDCancer associated fibroblasts have phenotypic and functional characteristics similar to the fibrocytes that represent a novel MDSC subsetOncoimmunology201549e103491826405600
   PubMedGoogle Scholar
• GarridoFCabreraTAptsiauriN“Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapyInt J Cancer2010127224925620178101
   PubMedGoogle Scholar
• ShepherdFADouillardJYBlumenscheinGRJrImmunotherapy for non-small cell lung cancer: novel approaches to improve patient outcomeJ Thorac Oncol20116101763177321876456
   PubMed Web of Science ®Google Scholar
• MigaliCMilanoMTrapaniDStrategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondTher Adv Med Oncol20168536037427583028
   PubMedGoogle Scholar
• VoutsadakisIAImmune blockade inhibition in breast cancerAnticancer Res201636115607562227793883
   PubMedGoogle Scholar
• McArthurHLDiabAPageDBA pilot study of preoperative single-dose ipilimumab and/or cryoablation in women with early-stage breast cancer with comprehensive immune profilingClin Cancer Res201622235729573727566765
   PubMed Web of Science ®Google Scholar
• TringlerBZhuoSPilkingtonGB7-h4 is highly expressed in ductal and lobular breast cancerClin Cancer Res20051151842184815756008
   PubMed Web of Science ®Google Scholar
• AbadiYMJeonHOhaegbulamKCHost b7x promotes pulmonary metastasis of breast cancerJ Immunol201319073806381423455497
   PubMedGoogle Scholar
• HerbertzSSawyerJSStauberAJClinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathwayDrug Des Devel Ther2015944794499
   PubMed Web of Science ®Google Scholar
• EwanKBOketch-RabahHARavaniSAShyamalaGMosesHLBarcellos-HoffMHProliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult miceAm J Pathol2005167240941716049327
   PubMedGoogle Scholar
• BandAMLaihoMCrosstalk of TGF-β and estrogen receptor signaling in breast cancerJ Mammary Gland Biol Neoplasia201116210911521390570
   PubMed Web of Science ®Google Scholar
• ImamuraTHikitaAInoueYThe roles of TGF-β signaling in carcinogenesis and breast cancer metastasisBreast Cancer201219211812422139728
   PubMed Web of Science ®Google Scholar
• SinghGSinghSKKönigASequential activation of NFAT and c-Myc transcription factors mediates the TGF-beta switch from a suppressor to a promoter of cancer cell proliferationJ Biol Chem201028535272412725020516082
   PubMedGoogle Scholar
• ChangNSTransforming growth factor-beta protection of cancer cells against tumor necrosis factor cytotoxicity is counteracted by hyaluronidase (review)Int J Mol Med1998266536599850732
   PubMedGoogle Scholar
• TaubeJHHerschkowitzJIKomurovKCore epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypesProc Natl Acad Sci U S A201010735154491545420713713
   PubMed Web of Science ®Google Scholar
• JainPAlahariSKBreast cancer stem cells: a new challenge for breast cancer treatmentFront Biosci (Landmark Ed)2011161824183221196267
   PubMed Web of Science ®Google Scholar
• WhitesideTLRegulatory T cell subsets in human cancer: are they regulating for or against tumor progression?Cancer Immunol Immunother2014631677224213679
   PubMed Web of Science ®Google Scholar
• IliopoulosDHirschHAStruhlKAn epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformationCell2009139469370619878981
   PubMed Web of Science ®Google Scholar
• IliopoulosDJaegerSAHirschHABulykMLStruhlKSTAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancerMol Cell201039449350620797623
   PubMed Web of Science ®Google Scholar
• KorkayaHLiuSWichaMSBreast cancer stem cells, cytokine networks, and the tumor microenvironmentJ Clin Invest2011121103804380921965337
   PubMed Web of Science ®Google Scholar
• SullivanNJSasserAKAxelAEInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cellsOncogene200928332940294719581928
   PubMed Web of Science ®Google Scholar
• XiaoPWanXCuiBInterleukin 33 in tumor microenvironment is crucial for the accumulation and function of myeloid-derived suppressor cellsOncoimmunology201551e106377226942079
   PubMedGoogle Scholar
• KanzakiHShinoharaFSuzukiMA-disintegrin and metalloproteinase (ADAM) 17 enzymatically degrades interferon-gammaSci Rep201663225927573075
   PubMedGoogle Scholar
• ParkSCheonSChoDThe dual effects of interleukin-18 in tumor progressionCell Mol Immunol20074532933517976312
   PubMedGoogle Scholar
• EissaSAZakiSAEl-MaghrabySMKadryDYImportance of serum IL-18 and RANTES as markers for breast carcinoma progressionJ Egypt Natl Canc Inst2005171515516353083
   PubMedGoogle Scholar
• HsingCHChengHCHsuYHUpregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcomeClin Cancer Res201218371372522186257
   PubMedGoogle Scholar
• HsuYHHsingCHLiCFAnti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine modelsJ Immunol201218841981199122238453
   PubMedGoogle Scholar
• LangowskiJLZhangXWuLIL-23 promotes tumour incidence and growthNature2006442710146146516688182
   PubMed Web of Science ®Google Scholar
• HamidullahChangkijaBKonwarRRole of interleukin-10 in breast cancerBreast Cancer Res Treat20121331112122057973
   PubMed Web of Science ®Google Scholar
• ZhouBPHuMCMillerSAHER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathwayJ Biol Chem2000275118027803110713122
   PubMed Web of Science ®Google Scholar
• MocellinSRossiCRPilatiPNittiDTumor necrosis factor, cancer and anticancer therapyCytokine Growth Factor Rev2005161355315733831
   PubMed Web of Science ®Google Scholar
• BaumgartenSCFrasorJMinireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancersMol Endocrinol201226336037122301780
   PubMedGoogle Scholar
• DonatoNJKlostergaardJDistinct stress and cell destruction pathways are engaged by TNF and ceramide during apoptosis of MCF-7 cellsExp Cell Res2004294252353315023539
   PubMedGoogle Scholar
• BalkwillFTumour necrosis factor and cancerNat Rev Cancer20099536137119343034
   PubMed Web of Science ®Google Scholar
• ConnellyLBarhamWOnishkoHMInhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burdenOncogene201130121402141221076466
   PubMed Web of Science ®Google Scholar
• DattaJRosemblitCBerkEProgressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restorationOncoimmunology2015410e102230126451293
   PubMedGoogle Scholar
• WatsonAPEvansRLEglandKAMultiple functions of sushi domain containing 2 (SUSD2) in breast tumorigenesisMol Cancer Res2013111748523131994
   PubMedGoogle Scholar
• StannardKACollinsPMItoKGalectin inhibitory disaccharides promote tumour immunity in a breast cancer modelCancer Lett201029929511020826047
   PubMed Web of Science ®Google Scholar
• SalatinoMDalotto-MorenoTRabinovichGAThwarting galectin-induced immunosuppression in breast cancerOncoimmunology201325e2407723762796
   PubMedGoogle Scholar
• Dalotto-MorenoTCrociDOCerlianiJPTargeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic diseaseCancer Res20137331107111723204230
   PubMed Web of Science ®Google Scholar
• RicciardiMZanottoMMalpeliGEpithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cellsBr J Cancer201511261067107525668006
   PubMed Web of Science ®Google Scholar
• PuccettiPFallarinoFItalianoAAccumulation of an endogenous tryptophan-derived metabolite in colorectal and breast cancersPLoS One2015104e012204625881064
   PubMedGoogle Scholar
• LevinaVSuYGorelikEImmunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formationClin Dev Immunol2012201217302922654951
   PubMed Web of Science ®Google Scholar
• WelteTRosenJMZhangXHFatal attraction: TICs and MDSCsCell Cycle201615192545254627574951
   PubMed Web of Science ®Google Scholar
• PengDTanikawaTLiWMyeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signalingCancer Res201676113156316527197152
   PubMedGoogle Scholar
• ForghaniPWallerEKPoly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancerBreast Cancer Res Treat20151531213026208484
   PubMed Web of Science ®Google Scholar
• AlizadehDTradMHankeNTDoxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancerCancer Res201474110411824197130
   PubMed Web of Science ®Google Scholar
• VinayDSRyanEPPawelecGImmune evasion in cancer: mechanistic basis and therapeutic strategiesSemin Cancer Biol201535SupplS185S19825818339
   PubMed Web of Science ®Google Scholar
• Breakthrough of the year 2013. Notable developmentsScience201334261651435144124357296
   PubMedGoogle Scholar